Join to View Full Profile
1365 Clifton Rd NeAtlanta, GA 30322
Phone+1 404-778-1900
Fax+1 404-778-3260
Dr. Kaufman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Jonathan Kaufman, MD is an oncologist based in Atlanta, GA, with a subspecialty in hematologic oncology. He completed his fellowship and residency at Emory University School of Medicine after graduating from the Medical College of Georgia at Augusta University in 1999. Dr. Kaufman has extensive experience in treating conditions like AL amyloidosis, multiple myeloma and waldenstrom macroglobulinamia among others. He has multiple publications to his name, and he has led clinical trials as the Principal Investigator, including trials focusing on treatments for newly diagnosed and relapsed/refractory multiple myeloma.
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2001 - 2005- Emory University School of MedicineResidency, Internal Medicine, 1999 - 2001
Medical College of Georgia at Augusta UniversityClass of 1999
Certifications & Licensure
GA State Medical License 2003 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification Cerner Patient Portal and Powerchart, Cerner Corporation, 2015-2017
- CMS Meaningful Use Stage 2 Certification P2 Sentinel, Cerner Corporation, 2015-2017
Clinical Trials
- Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma Start of enrollment: 2022 Oct 19
Roles: Principal Investigator, Contact
- A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2017 Oct 04
Roles: Principal Investigator
Publications & Presentations
PubMed
- What is the best induction for myeloma for the fit patient?Nishi Nilesh Shah, Jonathan L Kaufman
Hematology. American Society of Hematology. Education Program. 2025-12-05 - Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS.Paula Rodriguez-Otero, Peter M Voorhees, Mario Boccadoro, Jacob Laubach, Hermann Einsele
Clinical Lymphoma, Myeloma & Leukemia. 2025-10-01 - 3 citationsEarly CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy.Alyssa M Duffy, Anshika Goenka, Maryam I Azeem, Azmain Taz, Sayalee V Potdar
The Journal of Clinical Investigation. 2025-10-01
Abstracts/Posters
- Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...Jonathan L. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple ...Jonathan L. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...Jonathan L. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Challenges in Myeloma Therapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based...2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
Jonathan Kaufman, MD, Talks Targeting BCL-2 with Venetoclax and Dexamethasone in R/R MMMay 12th, 2021
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
